SEC Company Response from Novo Integrated Sciences, Inc. (NVOS) (CIK 0001138978) — Apr 26, 2022
Novo Integrated Sciences, Inc. (NVOS) (CIK 0001138978)
Date: April 26, 2022 · CIK: 0001138978 · Accession: 0001493152-22-011240
AI Filing Summary & Sentiment
File numbers found in text: 333-264360
Letter
NOVO INTEGRATED SCIENCES, INC.
NE 2nd Street, Suite 100
Bellevue, WA 98004
(206) 617-9797
April 26, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F. Street, N.E.
Washington, D.C. 20549
Attention: Mr. Kyle Wiles and Mr. Josh Shainess
Re: Novo Integrated Sciences, Inc.
Registration Statement on Form S-3
File Number 333-264360
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Novo Integrated Sciences, Inc. (the “Company”) hereby respectfully requests acceleration of the effectiveness of the Company’s Registration Statement on Form S-3, File Number 333-264360, so that it will be declared effective on Thursday, April 28, 2022 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
This letter will confirm that the Company acknowledges that:
● should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
● the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact our legal counsel, Craig D. Linder, Esq. of Anthony L.G., PLLC, at (561) 514-0936, if you have any questions concerning this request.
Very
truly yours,
NOVO
INTEGRATED SCIENCES, INC.
Show Raw Text
CORRESP
1
filename1.htm
NOVO
INTEGRATED SCIENCES, INC.
11120
NE 2nd Street, Suite 100
Bellevue,
WA 98004
(206)
617-9797
April
26, 2022
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F. Street, N.E.
Washington,
D.C. 20549
Attention:
Mr. Kyle Wiles and Mr. Josh Shainess
Re:
Novo
Integrated Sciences, Inc.
Registration
Statement on Form S-3
File
Number 333-264360
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, Novo Integrated Sciences, Inc. (the “Company”) hereby
respectfully requests acceleration of the effectiveness of the Company’s Registration Statement on Form S-3, File Number 333-264360,
so that it will be declared effective on Thursday, April 28, 2022 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
This
letter will confirm that the Company acknowledges that:
●
should
the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare
the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
●
the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the
Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission
or any person under the federal securities laws of the United States.
Please
contact our legal counsel, Craig D. Linder, Esq. of Anthony L.G., PLLC, at (561) 514-0936, if you have any questions concerning this
request.
Very
truly yours,
NOVO
INTEGRATED SCIENCES, INC.
By:
/s/
Robert Mattacchione
Name:
Robert
Mattacchione
Title:
Chief
Executive Officer